NO20014508D0 - Fremgangsmåte for acylering av peptider, og nye acyleringsmidler - Google Patents

Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Info

Publication number: NO20014508D0
Authority: NO; Norway
Prior art keywords: acylating; new; peptides; agents; acylating agents
Prior art date: 1999-03-17

Application number

NO20014508A

Other languages

English (en)

Norwegian (no)

Other versions

NO20014508L (no

Inventor

Louis Brammer Hansen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-17

Filing date

2001-09-17

Publication date

2001-09-17

2001-09-17 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2001-09-17 Publication of NO20014508D0 publication Critical patent/NO20014508D0/no

2001-09-17 Publication of NO20014508L publication Critical patent/NO20014508L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Analytical Chemistry (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

NO20014508A 1999-03-17 2001-09-17 Fremgangsmåte for acylering av peptider, og nye acyleringsmidler NO20014508L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP99610019		1999-03-17
PCT/DK2000/000117 WO2000055119A1 (fr)	1999-03-17	2000-03-16	Methode d'acylation de peptides et nouveaux agents d'acylation
EP00910573A EP1163211B1 (fr)	1999-03-17	2000-03-16	Methode d'acylation de peptides et proteines

Publications (2)

Publication Number	Publication Date
NO20014508D0 true NO20014508D0 (no)	2001-09-17
NO20014508L NO20014508L (no)	2001-09-17

Family

ID=26074622

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20014508A NO20014508L (no)	1999-03-17	2001-09-17	Fremgangsmåte for acylering av peptider, og nye acyleringsmidler

Country Status (16)

Country	Link
EP (2)	EP1163211B1 (fr)
CN (1)	CN1344248A (fr)
AT (1)	ATE409193T1 (fr)
AU (1)	AU3273500A (fr)
BR (1)	BR0009040A (fr)
CA (1)	CA2361830A1 (fr)
CZ (1)	CZ20013018A3 (fr)
DE (1)	DE60040333D1 (fr)
ES (1)	ES2315226T3 (fr)
HU (1)	HUP0200297A3 (fr)
IL (1)	IL144989A0 (fr)
NO (1)	NO20014508L (fr)
PL (1)	PL351326A1 (fr)
RU (1)	RU2001128068A (fr)
WO (1)	WO2000055119A1 (fr)
ZA (1)	ZA200106884B (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1412384B1 (fr)	2001-06-28	2007-12-26	Novo Nordisk A/S	Formulation stable de glp-1 modifie
EP1421102A2 (fr) *	2001-07-24	2004-05-26	Novo Nordisk A/S	Procede pour produire des polypeptides acyles
WO2003010186A2 (fr) *	2001-07-24	2003-02-06	Novo Nordisk A/S	Procede de production de polypeptides acyles
US20030082671A1 (en)	2001-07-24	2003-05-01	Thomas Hoeg-Jensen	Method for making acylated polypeptides
US7595172B2 (en)	2001-07-24	2009-09-29	Novo Nordisk A/S	Method for making acylated polypeptides
CA2458371A1 (fr) *	2001-08-23	2003-03-06	Eli Lilly And Company	Analogues de glp-1 (glucagon-like peptide 1)
DE60328112D1 (de) *	2002-09-25	2009-08-06	Novo Nordisk As	Verfahren zur herstellung acylierter peptide
EP1543030A2 (fr)	2002-09-25	2005-06-22	Theratechnologies Inc.	Peptides glp-1 modifies a activite biologique accrue
US7273921B2 (en)	2002-09-25	2007-09-25	Novo Nordisk A/S	Method for producing acylated peptides
CN1812808B (zh)	2003-06-03	2012-07-04	诺沃挪第克公司	稳定化的药物肽组合物
BRPI0410972C1 (pt)	2003-06-03	2021-05-25	Novo Nordisk As	método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
EP1633391B1 (fr)	2003-06-03	2011-10-19	Novo Nordisk A/S	Compositions peptidiques pharmaceutiques stabilisees
DK3300721T4 (da)	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
PL1789434T3 (pl)	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
WO2006037810A2 (fr)	2004-10-07	2006-04-13	Novo Nordisk A/S	Composes de glp-1 a action prolongee
JP5107713B2 (ja)	2004-10-07	2012-12-26	ノヴォノルディスクアー／エス	遅延性のエキセンディン−４化合物
CN106137952B (zh)	2004-11-12	2020-11-17	诺和诺德公司	促胰岛素肽的稳定制剂
CN102027005A (zh)	2008-05-15	2011-04-20	诺沃-诺迪斯克有限公司	通过固相合成制备的肽的纯化
CN106317164A (zh)	2008-09-12	2017-01-11	诺沃—诺迪斯克有限公司	酰化肽或蛋白的方法
WO2010070252A1 (fr)	2008-12-15	2010-06-24	Zealand Pharma A/S	Analogues du glucagon
JP5635531B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
JP5635529B2 (ja)	2008-12-15	2014-12-03	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
NZ593813A (en)	2008-12-15	2013-02-22	Zealand Pharma As	Glucagon analogues
ME02220B (me)	2009-07-13	2016-02-20	Zealand Pharma As	Analozi acilovanog glukagona
SG184988A1 (en)	2010-04-27	2012-11-29	Zealand Pharma As	Peptide conjugates of glp-1 receptor agonists and gastrin and their use
WO2011161125A1 (fr)	2010-06-23	2011-12-29	Novo Nordisk A/S	Dérivés d'insuline contenant des liaisons disulfure supplémentaires
AR081975A1 (es)	2010-06-23	2012-10-31	Zealand Pharma As	Analogos de glucagon
EP2585482B1 (fr)	2010-06-24	2019-03-27	Zealand Pharma A/S	Analogues de glucagon
MA34913B1 (fr)	2011-01-20	2014-02-01	Zealand Pharma As	Combinaison d'analogues du glucagon acylé à des analogues d'insuline
WO2012150503A2 (fr)	2011-05-03	2012-11-08	Zealand Pharma A/S	Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
EP2707713A2 (fr)	2011-05-10	2014-03-19	Zealand Pharma A/S	Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
CA2853884A1 (fr)	2011-11-03	2013-05-10	Zealand Pharma A/S	Conjugues de peptide agoniste du recepteur du glp-1 et de gastrine
KR20150006052A (ko)	2012-05-03	2015-01-15	질랜드 파마 에이/에스	글루카곤-유사 펩타이드-2 (ｇｌｐ-2) 유사체
WO2013164483A1 (fr)	2012-05-03	2013-11-07	Zealand Pharma A/S	Composés agonistes doubles du gip-glp-1 et méthodes
MY170671A (en)	2012-07-23	2019-08-26	Zealand Pharma As	Glucagon analogues
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en)	2012-12-21	2017-07-28	Sanofi Sa	Functionalized exendin-4 derivatives
RS62633B1 (sr)	2013-03-15	2021-12-31	Protagonist Therapeutics Inc	Analozi hepcidina i njihove primene
EP3010546B1 (fr)	2013-06-20	2017-08-09	Novo Nordisk A/S	Dérivés glp-1 et leurs utilisations
BR112015032875A2 (pt)	2013-07-04	2017-11-07	Novo Nordisk As	derivados de peptídeos do tipo glp-1, e usos dos mesmos
SI3057984T1 (sl)	2013-10-17	2018-10-30	Zealand Pharma A/S	Acilirani glukagonski analogi
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
US10093713B2 (en)	2013-11-06	2018-10-09	Zealand Pharma A/S	GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (ru)	2013-11-06	2020-07-27	Зилэнд Фарма А/С	Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
EP3080149A1 (fr)	2013-12-13	2016-10-19	Sanofi	Agonistes mixtes des récepteurs du glp-1/glucagon
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (fr)	2013-12-13	2015-06-18	Sanofi	Agonistes mixtes des récepteurs glp-1/gip
WO2015086730A1 (fr)	2013-12-13	2015-06-18	Sanofi	Analogues peptidiques de l'exendine 4 non acylés
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
SI3143037T1 (sl)	2014-05-16	2021-11-30	Protagonist Therapeutics, Inc.	Antagonisti integrin alpha4beta7 tioeterskih peptidov
CN104558097A (zh) *	2014-05-20	2015-04-29	广东东阳光药业有限公司	肽的酰化方法
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
CN107206254B (zh)	2014-07-17	2021-08-24	领导医疗有限公司	白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
WO2016054445A1 (fr)	2014-10-01	2016-04-07	Protagonist Therapeutics, Inc.	Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine
WO2016054411A1 (fr)	2014-10-01	2016-04-07	Protagonist Therapeutics, Inc.	NOUVEAUX ANTAGONISTES PEPTIDIQUES MONOMÈRES ET DIMÈRES DE α4β7
TWI705973B (zh)	2014-10-29	2020-10-01	丹麥商西蘭製藥公司	Ｇｉｐ促效劑化合物及方法
JP6730278B2 (ja)	2014-11-27	2020-07-29	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
US10392428B2 (en)	2014-12-17	2019-08-27	Novo Nordisk A/S	GLP-1 derivatives and uses thereof
CN107567459B (zh)	2015-03-18	2021-09-24	西兰制药公司	胰淀素类似物
TWI707867B (zh)	2015-04-16	2020-10-21	丹麥商西蘭製藥公司	醯化之昇糖素類似物
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (fr)	2015-12-30	2017-07-06	Protagonist Therapeutics, Inc.	Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree
EP3196206A1 (fr)	2016-01-20	2017-07-26	Lonza Ltd	Procédé de préparation de liraglutide
EP3205660A1 (fr)	2016-02-10	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Procédé de préparation de peptides à liaison pswang
DK3405476T3 (da)	2016-01-20	2024-05-21	Polypeptide Laboratories Holding Ppl Ab	Fremgangsmåde til fremstilling af peptider med psWANG linker
EP3205664A1 (fr)	2016-02-11	2017-08-16	Polypeptide Laboratories Holding (PPL) AB	Procédé de préparation de liraglutide utilisant un lieur bal
WO2017165676A1 (fr)	2016-03-23	2017-09-28	Protagonist Therapeutics, Inc.	Procédés de synthèse d'antagonistes de peptide α4β7
TWI784968B (zh)	2016-09-09	2022-12-01	丹麥商西蘭製藥公司	澱粉素類似物
MA46780A (fr)	2016-11-07	2019-09-11	Novo Nordisk As	Esters à dchbs actif de composés peg et leur utilisation
AU2017373651B2 (en)	2016-12-05	2022-03-10	Nuritas Limited	Compositions comprising peptide wkdeagkplvk
EP3329930A1 (fr)	2016-12-05	2018-06-06	Nuritas Limited	Compositions pharmaceutiques
WO2018103868A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
WO2018104561A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
WO2018104558A1 (fr)	2016-12-09	2018-06-14	Zealand Pharma A/S	Agonistes doubles de glp-1/glp-2 acylés
TWI847306B (zh)	2017-08-24	2024-07-01	丹麥商諾佛儂迪克股份有限公司	Ｇｌｐ-１組成物及其用途
EP4092038A1 (fr)	2017-09-11	2022-11-23	Protagonist Therapeutics, Inc.	Peptides d'agoniste opioïde et leurs utilisations
EP4501952A3 (fr)	2018-02-08	2025-04-16	Protagonist Therapeutics, Inc.	Mimétiques d'hepcidine conjugués
AU2019228639A1 (en)	2018-02-27	2020-09-17	Zp Spv 3 K/S	Compstatin analogues and their medical uses
EP3820883A4 (fr)	2018-07-12	2022-04-20	Protagonist Therapeutics, Inc.	Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
EP3897570A1 (fr)	2018-12-19	2021-10-27	KRKA, d.d., Novo mesto	Composition pharmaceutique comprenant un analogue de glp -1
CN111909073A (zh) *	2019-05-10	2020-11-10	江苏万邦医药科技有限公司	一种制备高纯度脂肪酸衍生物的方法
CA3138715A1 (fr)	2019-06-14	2020-12-17	Zealand Pharma A/S	Composition pharmaceutique parenterale d'agoniste de glp1/2 double
KR20220044487A (ko)	2019-06-17	2022-04-08	바이오마크 파마슈티칼스 리미티드	펩티드 및 포도막염의 치료에 있어서의 그의 사용 방법
CN116082455A (zh)	2019-07-10	2023-05-09	领导医疗有限公司	白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
ES3049784T3 (en)	2019-08-27	2025-12-18	Zp Spv 3 K/S	Compstatin analogues and their medical uses
MX2022002633A (es)	2019-09-03	2022-06-02	Protagonist Therapeutics Inc	Mimeticos de hepcidina conjugada.
CN114746119A (zh)	2019-09-27	2022-07-12	詹森生物科技公司	抗-ceacam抗体及其用途
WO2021123228A1 (fr)	2019-12-18	2021-06-24	Krka, D.D., Novo Mesto	Composition pharmaceutique comprenant un analogue de glp-1
SI4090670T1 (sl)	2020-01-15	2025-08-29	Janssen Biotech, Inc.	Peptidni zaviralci receptorja interlevkina-23 in njihova uporaba za zdravljenje vnetnih bolezni
EP4090669A4 (fr)	2020-01-15	2024-11-20	Janssen Biotech, Inc.	Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
BR112022013795A2 (pt)	2020-02-18	2022-09-13	Novo Nordisk As	Composição farmacêutica líquida, e, kit
US20230129788A1 (en)	2020-03-30	2023-04-27	Zealand Pharma A/S	Glp-1/glp-2 dual agonists
US20230110689A1 (en)	2020-03-30	2023-04-13	Zealand Pharma A/S	Agonist combination
IL316550A (en)	2020-11-20	2024-12-01	Janssen Pharmaceutica Nv	Compositions of interleukin-23 receptor peptide inhibitors
WO2022157747A2 (fr)	2021-01-25	2022-07-28	Mylan Ireland Limited	Compositions peptidiques pharmaceutiques et leurs procédés de préparation
IL310061A (en)	2021-07-14	2024-03-01	Janssen Biotech Inc	Peptide inhibitors linked to fatty residues of the interleukin-23 receptor
CA3228429A1 (fr)	2021-09-03	2023-03-09	Mikkel Askjar Agersnap	Regime posologique
IL319599A (en)	2022-09-19	2025-05-01	Zealand Pharma As	Combination therapy
WO2024068848A1 (fr)	2022-09-28	2024-04-04	Zealand Pharma A/S	Méthodes de traitement de l'obésité
WO2024261076A1 (fr)	2023-06-21	2024-12-26	Zealand Pharma A/S	Perte de poids
TW202515598A (zh)	2023-06-21	2025-04-16	丹麥商西蘭製藥公司	具有增進性能之類似物
TW202517291A (zh)	2023-06-30	2025-05-01	丹麥商西蘭製藥公司	組合療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5336782A (en)	1991-04-24	1994-08-09	Kuraray Co., Ltd.	Long chain carboxylic acid imide ester
PT938502E (pt)	1996-07-11	2005-02-28	Novo Nordisk As	Metodo selectivo por acilacao
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
AU4112497A (en) *	1996-08-30	1998-03-19	Novo Nordisk A/S	Glp-2 derivatives
AU3247799A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action

2000
- 2000-03-16 PL PL00351326A patent/PL351326A1/xx unknown
- 2000-03-16 WO PCT/DK2000/000117 patent/WO2000055119A1/fr not_active Ceased
- 2000-03-16 CA CA002361830A patent/CA2361830A1/fr not_active Abandoned
- 2000-03-16 HU HU0200297A patent/HUP0200297A3/hu unknown
- 2000-03-16 DE DE60040333T patent/DE60040333D1/de not_active Expired - Lifetime
- 2000-03-16 IL IL14498900A patent/IL144989A0/xx unknown
- 2000-03-16 RU RU2001128068/04A patent/RU2001128068A/ru unknown
- 2000-03-16 CZ CZ20013018A patent/CZ20013018A3/cs unknown
- 2000-03-16 AT AT00910573T patent/ATE409193T1/de not_active IP Right Cessation
- 2000-03-16 CN CN00805003.1A patent/CN1344248A/zh active Pending
- 2000-03-16 EP EP00910573A patent/EP1163211B1/fr not_active Expired - Lifetime
- 2000-03-16 EP EP08002200.7A patent/EP1956000B1/fr not_active Expired - Lifetime
- 2000-03-16 BR BR0009040-9A patent/BR0009040A/pt not_active Application Discontinuation
- 2000-03-16 ES ES00910573T patent/ES2315226T3/es not_active Expired - Lifetime
- 2000-03-16 AU AU32735/00A patent/AU3273500A/en not_active Abandoned
2001
- 2001-08-21 ZA ZA200106884A patent/ZA200106884B/xx unknown
- 2001-09-17 NO NO20014508A patent/NO20014508L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ES2315226T3 (es)	2009-04-01
ZA200106884B (en)	2002-03-01
CN1344248A (zh)	2002-04-10
BR0009040A (pt)	2001-12-18
HUP0200297A2 (en)	2002-06-29
IL144989A0 (en)	2002-06-30
AU3273500A (en)	2000-10-04
RU2001128068A (ru)	2004-02-20
NO20014508L (no)	2001-09-17
DE60040333D1 (de)	2008-11-06
WO2000055119A1 (fr)	2000-09-21
EP1956000B1 (fr)	2016-10-05
PL351326A1 (en)	2003-04-07
EP1956000A1 (fr)	2008-08-13
CA2361830A1 (fr)	2000-09-21
CZ20013018A3 (cs)	2002-02-13
EP1163211A1 (fr)	2001-12-19
EP1163211B1 (fr)	2008-09-24
ATE409193T1 (de)	2008-10-15
HUP0200297A3 (en)	2002-09-30

Publication	Publication Date	Title
NO20014508D0 (no)	2001-09-17	Fremgangsmåte for acylering av peptider, og nye acyleringsmidler
CA2270289A1 (fr)	1998-05-14	Proteines a concentration amelioree en acides amines essentiels
DE69739035D1 (de)	2008-11-20	Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
DK0535091T3 (da)	1996-05-06	Knogleinducerende farmaceutiske formuleringer
FI20050243A7 (fi)	2005-03-07	Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi
DE69630708D1 (de)	2003-12-18	An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
HU9200548D0 (en)	1992-04-28	Improved activity process of recombined proteins
BR0010720A (pt)	2002-06-11	Peptìdeos de neisseria antigênicos
ATE168719T1 (de)	1998-08-15	Osteogene peptide
DE60023860D1 (de)	2005-12-15	Verfahren zur herstellung von rekombinanten peptiden
SE8801701D0 (sv)	1988-05-05	Production technology based on enzymic method
ITMI951764A0 (it)	1995-08-09	Peptide sintetasi ingegnerizzate e loro impiego per la produzione via non-ribosomale di peptidi
PT896615E (pt)	2003-01-31	Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
ATE211765T1 (de)	2002-01-15	Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE60236330D1 (de)	2010-06-17	Biologisch aktive Peptide
DE3852105D1 (de)	1994-12-15	Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
DK595187A (da)	1988-07-21	Minactivin og fremgangsmaade til fremstilling deraf
DE59109235D1 (de)	2002-05-29	Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DK0975742T3 (da)	2005-02-14	Aminopeptidase, der stammer fra Bacillus licheniformis og fremgangsmåde til fremstilling af et natur-type proteiner
DE69922150D1 (de)	2004-12-30	Deoxyhypusin reagenz und peptide
TH17162A (th)	1995-12-14	สารผสมฟอกจากที่ประกอบด้วยเอนไซม์โพรทีเอส
WO2004011491A3 (fr)	2004-04-29	Polypeptides purifies d'enterococcus faecalis

Legal Events

Date	Code	Title	Description
2004-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application